BCBonaventura ClotetMD, PhDVideoHIVHIV DART and Emerging Viruses 2018Barry-Wainberg DART Achievement Award Lecture: Overview of the research conducted at the Irsicaixa Foundation | Bonaventura Clotet, MD, PhDView Video
VideoOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018Targeted agents and monoclonal antibodies | Joseph Ciccolini, PharmD, PhDView Video
VideoOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018Cytotoxic agents | Markus Jörger, MD, PhDView Video
HGHoward GurneyMBBS, FRACPVideoOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018Rationale for selecting combinations with immunotherapy | Howard Gurney, MBBS, FRACPView Video
VideoOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018Immunotherapy of prostate cancer and urothelial cancer. Future directions | Winald GerritsenView Video
VideoOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018Drug-drug interaction management with DDI-Predictor | Michel Tod, PharmD, PhDView Video
VideoOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018Pharmacotherapy of Comorbities: Cancer Patients with HIV/AIDS | Michelle Rudek, PharmD, PhDView Video
RMRon MathijssenMD, PhDVideoOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018Drug-Drug interactions with targeted oncolytics (in particular PPIs and TKIs) | Ron MathijssenView Video
VideoOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018Clinical relevance of liquid biopsy in cancer patients | Catherine Alix-Panabières, PhDView Video
VideoOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018The value of surrogate endpoints in the benefit-risk assessment of new drugs | Gabe Sonke, MD, PhDView Video
VideoOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018How studies can be optimized by simultaneous use of PK/PD outcome measurement? | Alwin HuitemaView Video
JVLJeffrey V. LazarusPhD, MIH, MAVideoViral Hepatitis and Liver DiseaseInternational Viral Hepatitis Elimination Meeting (IVHEM) 2018Introduction Session 5 | Jeffrey Lazarus, PhD, MIH, MAView Video
